Retinal cases & brief reports · 2025
INTRAVITREAL FARICIMAB AS AN ADJUVANT IN THE MANAGEMENT OF TUBERCULAR UVEITIS.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alcibahy Yasmine, Julian Karina, Bonilla Maria Fernanda, Mohamed Ali, Amrani Sarah, Agarwal Aniruddha
Аннотация
PURPOSE: The objective of this study was to report the use of intravitreal faricimab used as an adjunct in the management of intraocular tuberculosis in a patient with occlusive retinal vasculitis and choroiditis.
METHODS: This is a case report.
RESULTS: A 27-year-old Asian man presented with bilateral choroiditis and occlusive retinal vasculitis complicated by retinal neovascularization and vitreous hemorrhage in one eye. The patient had a positive tuberculin skin test, indeterminate interferon-gamma release assay, and Ghon focus on chest radiography. With a diagnosis of intraocular tuberculosis, the patient was treated with antitubercular therapy. Owing to the significant vitreous hemorrhage, he underwent pars plana vitrectomy in one eye. The patient received bilateral faricimab. Within a week of the injection, he had a near-complete resolution of the extensive choroidal and retinal vascular inflammation.
CONCLUSION: Intravitreal faricimab, given its angiopoietin-2 inhibition and antivascular endothelial growth factor action, maybe a helpful adjunct in intraocular tuberculosis. Whether angiopoietin-2 inhibition provides any additional benefit needs further evaluation in extensive studies.
METHODS: This is a case report.
RESULTS: A 27-year-old Asian man presented with bilateral choroiditis and occlusive retinal vasculitis complicated by retinal neovascularization and vitreous hemorrhage in one eye. The patient had a positive tuberculin skin test, indeterminate interferon-gamma release assay, and Ghon focus on chest radiography. With a diagnosis of intraocular tuberculosis, the patient was treated with antitubercular therapy. Owing to the significant vitreous hemorrhage, he underwent pars plana vitrectomy in one eye. The patient received bilateral faricimab. Within a week of the injection, he had a near-complete resolution of the extensive choroidal and retinal vascular inflammation.
CONCLUSION: Intravitreal faricimab, given its angiopoietin-2 inhibition and antivascular endothelial growth factor action, maybe a helpful adjunct in intraocular tuberculosis. Whether angiopoietin-2 inhibition provides any additional benefit needs further evaluation in extensive studies.